Literature DB >> 8377025

A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building.

L M Koymans1, N P Vermeulen, A Baarslag, G M Donné-Op den Kelder.   

Abstract

A homology model building study of cytochrome P450 2D6 has been carried out based on the crystal structure of cytochrome P450 101. The primary sequences of P450 101 and P450 2D6 were aligned by making use of an automated alignment procedure. This alignment was adjusted manually by matching alpha-helices (C, D, G, I, J, K and L) and beta-sheets (beta 3/beta 4) of P450 101 that are proposed to be conserved in membrane-bound P450s (Ouzounis and Melvin [Eur. J. Biochem., 198 (1991) 307]) to the corresponding regions in the primary amino acid sequence of P450 2D6. Furthermore, alpha-helices B, B' and F were found to be conserved in P450 2D6. No significant homology between the remaining regions of P450 101 and P450 2D6 could be found and these regions were therefore deleted. A 3D model of P450 2D6 was constructed by copying the coordinates of the residues from the crystal structure of P450 101 to the corresponding residues in P450 2D6. The regions without a significant homology with P450 101 were not incorporated into the model. After energy-minimization of the resulting 3D model of P450 2D6, possible active site residues were identified by fitting the substrates debrisoquine and dextrometorphan into the proposed active site. Both substrates could be positioned into a planar pocket near the heme region formed by residues Val370, Pro371, Leu372, Trp316, and part of the oxygen binding site of P450 2D6. Furthermore, the carboxylate group of either Asp100 or Asp301 was identified as a possible candidate for the proposed interaction with basic nitrogen atom(s) of the substrates.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8377025     DOI: 10.1007/bf00125503

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  28 in total

1.  A single amino acid substitution converts cytochrome P450(14DM) to an inactive form, cytochrome P450SG1: complete primary structures deduced from cloned DNAS.

Authors:  N Ishida; Y Aoyama; R Hatanaka; Y Oyama; S Imajo; M Ishiguro; T Oshima; H Nakazato; T Noguchi; U S Maitra
Journal:  Biochem Biophys Res Commun       Date:  1988-08-30       Impact factor: 3.575

2.  The active site of cytochrome P-450 nifedipine oxidase: a model-building study.

Authors:  G G Ferenczy; G M Morris
Journal:  J Mol Graph       Date:  1989-12

3.  Secondary structure prediction of 52 membrane-bound cytochromes P450 shows a strong structural similarity to P450cam.

Authors:  D R Nelson; H W Strobel
Journal:  Biochemistry       Date:  1989-01-24       Impact factor: 3.162

4.  Improved tools for biological sequence comparison.

Authors:  W R Pearson; D J Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

5.  High-resolution crystal structure of cytochrome P450cam.

Authors:  T L Poulos; B C Finzel; A J Howard
Journal:  J Mol Biol       Date:  1987-06-05       Impact factor: 5.469

6.  Optimal alignments in linear space.

Authors:  E W Myers; W Miller
Journal:  Comput Appl Biosci       Date:  1988-03

Review 7.  Analysis, design and modification of loop regions in proteins.

Authors:  J M Thornton; B L Sibanda; M S Edwards; D J Barlow
Journal:  Bioessays       Date:  1988 Feb-Mar       Impact factor: 4.345

8.  On the membrane topology of vertebrate cytochrome P-450 proteins.

Authors:  D R Nelson; H W Strobel
Journal:  J Biol Chem       Date:  1988-05-05       Impact factor: 5.157

9.  Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.

Authors:  R Ayesh; J R Idle; J C Ritchie; M J Crothers; M R Hetzel
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

10.  The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.

Authors:  U A Meyer; J Gut; T Kronbach; C Skoda; U T Meier; T Catin; P Dayer
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

View more
  11 in total

1.  An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine.

Authors:  D Marez; M Legrand; N Sabbagh; J M Lo-Guidice; P Boone; F Broly
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

2.  Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.

Authors:  S W Ellis; G P Hayhurst; T Lightfoot; G Smith; J Harlow; K Rowland-Yeo; C Larsson; J Mahling; C K Lim; C R Wolf; M G Blackburn; M S Lennard; G T Tucker
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

3.  Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity.

Authors:  G Smith; S Modi; I Pillai; L Y Lian; M J Sutcliffe; M P Pritchard; T Friedberg; G C Roberts; C R Wolf
Journal:  Biochem J       Date:  1998-05-01       Impact factor: 3.857

4.  An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.

Authors:  R C Halliday; B C Jones; D A Smith; N R Kitteringham; B K Park
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

5.  Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.

Authors:  G P Hayhurst; J Harlow; J Chowdry; E Gross; E Hilton; M S Lennard; G T Tucker; S W Ellis
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

6.  Application of molecular modeling for prediction of substrate specificity in cytochrome P450 1A2 mutants.

Authors:  Youbin Tu; Rahul Deshmukh; Meena Sivaneri; Grazyna D Szklarz
Journal:  Drug Metab Dispos       Date:  2008-08-14       Impact factor: 3.922

7.  Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol.

Authors:  S W Ellis; K Rowland; M J Ackland; E Rekka; A P Simula; M S Lennard; C R Wolf; G T Tucker
Journal:  Biochem J       Date:  1996-06-01       Impact factor: 3.857

8.  A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine.

Authors:  B Evert; E U Griese; M Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-10       Impact factor: 3.000

9.  In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestane.

Authors:  Amity Peterson; Zuping Xia; Gang Chen; Philip Lazarus
Journal:  Pharmacol Res Perspect       Date:  2017-04-27

10.  Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics.

Authors:  Luc Roumen; Marijn P A Sanders; Koen Pieterse; Peter A J Hilbers; Ralf Plate; Erica Custers; Marcel de Gooyer; Jos F M Smits; Ilona Beugels; Judith Emmen; Harry C J Ottenheijm; Dirk Leysen; J J R Hermans
Journal:  J Comput Aided Mol Des       Date:  2007-07-24       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.